1.01
5.61%
-0.06
Handel nachbörslich:
1.02
0.01
+0.99%
Hoth Therapeutics Inc Aktie (HOTH) Neueste Nachrichten
Hoth Therapeutics Inc [HOTH] Revenue clocked in at $0.00 million, down -25.69% YTD: What’s Next? - The DBT News
Balance Sheet Dive: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
C4 Therapeutics Inc (NASDAQ: CCCC) Up 14.34% This Year: What To Expect Next - Stocks Register
Hoth Therapeutics Inc (HOTH) Stock: Navigating a Year of Volatility - The InvestChronicle
Hoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data - MarketWatch
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ - StockTitan
Monopar Therapeutics' (MNPR) MNPR-101-Zr Shows Promising Tumor Targeting in Early Clinical Trial - BP Journal
Hoth Therapeutics Inc (HOTH) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Market Watch Highlights: Hoth Therapeutics Inc (HOTH) Ends on an Upturn Note at 1.12 - The Dwinnex
Hoth Therapeutics Inc [HOTH] Stock bought by Insider Knie Robb for $16750.0 - Knox Daily
AstraZeneca (NASDAQ: AZN) Stock Dips on Lung Cancer Drug Trial Setback - ABBO News
Relay Therapeutics Shows Promising Results with RLY-2608 in Breast Cancer Study - BP Journal
Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance - BP Journal
Hoth Therapeutics Inc: Rising -68.55% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Are Hoth Therapeutics Inc’shares a good deal? - US Post News
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - MSN
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - Zacks Investment Research
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - Yahoo Finance
Hoth Therapeutics (NASDAQ: HOTH) Stock Skyrockets Following Approval of HT-001 Phase 2a Human Trials - ABBO News
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Hoth Therapeutics ($HOTH) Advances to Phase 2a Trials with New Skin Toxicity Treatment - BP Journal
Hoth Therapeutics Inc (HOTH) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Gold Moves Higher; Science Applications International Posts Upbeat EarningsChargePoint Hldgs (NYSE:CHPT) - Benzinga
Hoth Therapeutics Reports Favorable Results for First-of-Its-Kind HT-001 Treatment of a Patient - MarketWatch
Dow Tumbles 1%; US Crude Oil Stocks FallSify Technologies (NASDAQ:SIFY) - Benzinga
HOTH’s valuation metrics: A comprehensive analysis - US Post News
Hoth reports rapid symptom relief in cancer treatment - Investing.com India
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial - StockTitan
US Stocks Edge Higher; Jobless Claims Fall To 227,000 - Benzinga
Hoth reports rapid symptom relief in cancer treatment - Investing.com
Hoth Therapeutics jumps as skin toxicity drug shows promise in one patient - XM
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 - StockTitan
Atara Biotherapeutics (ATRA) Secures Strategic Investments to Advance T-cell Immunotherapy Innovations - BP Journal
SPAR Group to Go Private in $2.50 Per Share Buyout by Highwire Capital - BP Journal
XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal
Applied DNA Sciences Inc. (NASDAQ: APDN): Expanding Horizons in DNA Technology and Clinical Testing - BP Journal
Hoth Therapeutics Inc (HOTH) rating initates by The Benchmark Company - Knox Daily
Hoth Therapeutics shares upgraded by EF Hutton on HT-001 potential - Investing.com
Hoth Therapeutics assumed with a Buy at EF Hutton - TipRanks
Titan Pharmaceuticals (TTNP) Announces Strategic Merger with KE Sdn. Bhd. - BP Journal
Hoth Therapeutics CEO purchases $16,750 in company stock - Investing.com
Hoth Therapeutics Inc (HOTH) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Hoth Therapeutics CEO purchases $16,750 in company stock By Investing.com - Investing.com Australia
ARCA Biopharma (ABIO) Announces Special Dividend Amid Merger with Oruka Therapeutics - BP Journal
Hoth Therapeutics Announces Positive Preclinical End Point Resul - GuruFocus.com
Hoth Therapeutics Announces Positive Final Results from 14-day P - GuruFocus.com
Hoth Therapeutics Inc (HOTH)’s Day in Review: Closing at 0.62, Up by 2.00 - The Dwinnex
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from HC Wainwright - Defense World
FDA Loophole Raises Concerns About Oncology Drug Approvals and More - OBR Oncology
Hoth and Aronnax partner for HT-KIT cancer therapy development - Yahoo Finance
Hoth and Aronnax partner for HT-KIT cancer therapy development - Pharmaceutical Technology
Hoth Therapeutics Inc (HOTH) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Hoth Therapeutics advances HT-KIT cancer drug study By Investing.com - Investing.com Canada
Hoth Therapeutics advances HT-KIT cancer drug study By Investing.com - Investing.com India
Hoth Therapeutics advances HT-KIT cancer drug study - Investing.com
Hoth Therapeutics advances HT-KIT cancer drug study By Investing.com - Investing.com Australia
Hoth Therapeutics Partners With Aronnax For HT-KIT Cancer Therapy - Contract Pharma
Hoth Therapeutics advances HT-KIT cancer drug study By Investing.com - Investing.com UK
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic - PR Newswire
ImmunityBio (IBRX) Advances Global Expansion and Immunotherapy Innovations Amid Volatile Stock Performance - BP Journal
Hoth Therapeutics shareholders approve key proposals - Investing.com
Hoth Therapeutics stock hits 52-week low at $0.6 amid market challenges - Investing.com
EGFR Inhibitors-Induced Skin Disorders Market to Observe Impressive Growth During the Study Period (2020–2034) | DelveInsight - 新浪香港
EGFR Inhibitors-Induced Skin Disorders Market to Observe - GlobeNewswire
EGFR Inhibitors-Induced Skin Disorders Market to Observe Impressive Growth During the Study Period (2020–2034) | DelveInsight - Yahoo Finance
Hoth Therapeutics stock hits 52-week low at $0.6 amid market challenges - Investing.com Canada
Is Hoth Therapeutics Inc (HOTH) positioned for future growth? - SETE News
A closer look at Hoth Therapeutics Inc (HOTH) is warranted - US Post News
Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Positive Close at 0.83 - The Dwinnex
Taking on analysts’ expectations and winning: Hoth Therapeutics Inc (HOTH) - SETE News
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Actelis Networks Inc [ASNS] moved down -8.00: Why It’s Important - The DBT News
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):